The Results of a Case Control Study of Gefitinib

Abstract

A case control study of gefitinib showed the following 3 important points. 1. Accompanying chronic interstitial pneumonia is a risk factor for higher frequency of drug induced lung diseases and poor prognosis. 2. Decreased amount of normal lung before treatment is also a risk factor for the frequency of drug induced lung diseases and poor prognosis. 3. Increased amount of the areas where respiratory movement is restricted due to adhesion improves prognosis.